Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT00005635
First received: May 2, 2000
Last updated: August 16, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: November 2001 (Final data collection date for primary outcome measure)